TCGA-66-2789-01A-01R-0980-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- ANGIOGENESIS+0.370
- TGF_BETA_SIGNALING+0.270
- PROTEIN_SECRETION+0.250
- UV_RESPONSE_DN+0.210
- COAGULATION+0.190
- ADIPOGENESIS+0.180
- DNA_REPAIR+0.140
- HYPOXIA+0.140
- KRAS_SIGNALING_UP+0.140
Top 10 suppressed
- MYC_TARGETS_V2-0.540
- INTERFERON_GAMMA_RESPONSE-0.370
- INTERFERON_ALPHA_RESPONSE-0.350
- TNFA_SIGNALING_VIA_NFKB-0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
- MITOTIC_SPINDLE-0.270
- ALLOGRAFT_REJECTION-0.210
- INFLAMMATORY_RESPONSE-0.180
- ESTROGEN_RESPONSE_EARLY-0.170
- IL6_JAK_STAT3_SIGNALING-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518416 | — | E | 0.720 |
| 2 | TCGA-DQ-5631-01A-01R-1873-07 | — | — | 0.720 |
| 3 | TCGA-XF-A9SV-01A-21R-A42T-07 | — | — | 0.709 |
| 4 | TCGA-18-3409-01A-01R-0980-07 | — | cohortSQ1 | 0.705 |
| 5 | SRR493955 | — | cohortSC | 0.688 |
| 6 | SRR8518380 | — | C | 0.669 |
| 7 | 4f0c3ed0-647a-422e-b771-f201f5d5d29e | — | — | 0.660 |
| 8 | df16e2f1-59a7-444d-9eab-c8d3b23b080d | — | — | 0.659 |
| 9 | SRR33532824 | — | D | 0.655 |
| 10 | a7bda5b9-9c95-4f90-bab6-10ab15ee2b48 | — | — | 0.654 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |